News about MRNA

Nasdaq Inc. added Moderna to its Nasdaq-100 index earlier this month; the index tracks the 100 largest non-financial companies listed on the Nasdaq. The move does not change the company's financial performance, but it raises visibility and prompts ETFs that mirror the index, such as Invesco QQQ Trust, to buy the stock. Invesco's ETF alone holds about $2 billion of Moderna, more than 2% of the $94 billion company, and roughly 80% of outstanding shares are now institutionally owned. The article argues this leaves fewer shares for individual investors, making the stock harder and more expensive for them to buy. It says the bigger driver remains the potential of Moderna's cancer vaccine intismeran autogene, combined with Merck's Keytruda, alongside COVID-19 and flu vaccine approvals, which contributed to the stock's 700% gain this year.